CIPLA and AUROPHARMA, both in Pharmaceuticals: Other. Monthly data through 2026-10-09. Change the comparison →
Share price change since Jan '19, the first month all 2 have a price: CIPLA +151%, AUROPHARMA +115%.
Rebased at 2019-01. Monthly closes from each company's history.
Months with a missing value are left as gaps.
The share price return over 3 years, split into net profit growth, share count change and the change in P/E.
CIPLA: share price rose 8% over 3 years: +21 pts from net profit growth, −13 pts from the P/E change.
AUROPHARMA: share price rose 99% over 3 years: +108 pts from net profit growth, −10 pts from the P/E change, +2 pts from share count change.
Segments are percentage points of the price return: price = P/E × net profit ÷ share count. These are the same numbers each company's own page shows.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | CIPLA | AUROPHARMA |
|---|---|---|
| Share Price | ₹1301.00 | ₹1693.00 |
| Market Cap | ₹1.05L cr | ₹98040 cr |
| P/E | 34.2x | 37.8x |
| P/B | 3.1x | 4.3x |
| P/S | 5.5x | 8.8x |
| ROCE | 14.0% | 13.0% |
| ROE | 9.0% | 11.4% |
| Operating margin | 21.0% | 32.0% |
| Revenue (TTM), indexed to 100 | ₹19012 cr | ₹11124 cr |
| Net Profit (TTM) | ₹3075 cr | ₹2592 cr |
| Debt / Equity | 0.0x | 0.2x |
| Cash Conversion Cycle | 205d | 174d |
| Promoter holding | 29.2% | 51.9% |
| FII Holding | 20.2% | 16.4% |
| DII Holding | 34.4% | 25.1% |
| 12M momentum | -13.3% | 48.6% |
| Drawdown from Peak | -21.4% | -1.4% |
| Cash conversion (3Y) | 0.8x | 1.0x |
| Interest cover | 100.0x | 18.2x |
| Share Count Change (1Y) | 0.0% | 0.0% |
| Volatility (1Y) | 20.8% | 26.0% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.